menu Search
Bdocin 500

Bdocin 500

capecitabine

Manufacturer:

BDR Pharmaceuticals

Distributor:

Detoxicare

Marketer:

Ambica
Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing
Concise Prescribing Info
Contents
Capecitabine
Indications/Uses
1st-line treatment of metastatic colorectal carcinoma when treatment w/ fluoropyrimidine therapy alone is preferred. Single agent for adjuvant treatment in patients w/ Dukes' C colon cancer who have undergone complete resection of primary tumor when treatment w/ fluoropyrimidine therapy alone is preferred. Monotherapy for metastatic breast cancer resistant to both paclitaxel & anthracycline-containing chemotherapy regimen or resistant to paclitaxel & for whom further anthracycline therapy is not indicated. In combination w/ docetaxel for metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.
Click to view Bdocin 500 detailed prescribing information
Dosage/Direction for Use
Metastatic CRC or of locally advanced or metastatic breast cancer; adjuvant treatment of colon cancer Monotherapy: 1,250 mg/m2 bid (morning & evening; equiv to 2,500 mg/m2 total daily dose) for 14 days followed by 7-day rest period. Adjuvant treatment in stage III colon cancer Recommended duration: 6 mth. Colon, colorectal & gastric cancer Combination therapy: Initially 800-1,000 mg/m2 bid for 14 days followed by 7-day rest period or to 625 mg/m2 bid when administered continuously. Metastatic breast cancer in combination w/ docetaxel 1,250 mg/m2 bid for 14 days followed by 7-day rest period + docetaxel 75 mg/m2 as 1 hr IV infusion every 3 wk. Premed w/ oral corticosteroid eg, dexamethasone prior to docetaxel administration.
Click to view Bdocin 500 detailed prescribing information
Overdosage
View Bdocin 500 overdosage for action to be taken in the event of an overdose.
Administration
Should be taken with food: Swallow w/ water w/in 30 min after a meal.
Contraindications
Hypersensitivity. History of severe & unexpected reactions to fluoropyrimidine therapy. Patients w/ known complete absence of dihydropyrimidine dehydrogenase activity; severe leukopenia, neutropenia, or thrombocytopenia. Treatment w/ sorivudine or its chemically related analogues eg, brivudine. Severe hepatic & renal (CrCl <30 mL/min) impairment. Pregnancy & lactation.
Click to view Bdocin 500 detailed prescribing information
Special Precautions
Carefully monitor patients w/ severe diarrhea; give fluid & electrolyte replacement if they become dehydrated. Dehydration; hand-foot syndrome; cardiotoxicity eg, MI, angina, dysrhythmias, cardiogenic shock, sudden death & electrocardiographic changes; pre-existing hypo- or hypercalcemia; CNS/peripheral nervous system disease eg, brain metastasis or neuropathy; DM or electrolyte disturbances; Closely monitor INR or prothrombin time in patients receiving concomitant oral coumarin-derivative anticoagulant. Not to be administered concomitantly w/ brivudine. Dihydropyrimidine dehydrogenase deficiency. Patients w/ ophthalmological complications eg, keratitis & corneal disorders, especially w/ history of eye disorders. Severe skin reactions eg, SJS & TEN. Hepatic & renal impairment. Childn. Elderly >60 yr.
Click to view Bdocin 500 detailed prescribing information
Use In Pregnancy & Lactation
Click to view Bdocin 500 detailed prescribing information
Adverse Reactions
Anorexia; diarrhea, vomiting, nausea, stomatitis, abdominal pain; palmar-plantar erythrodysesthesia syndrome, fatigue, asthenia. Herpes viral infection, nasopharyngitis, lower resp tract infection; neutropenia, anemia; dehydration, decreased wt; insomnia, depression; headache, lethargy, dizziness, paresthesia, dysgeusia; increased lacrimation, conjunctivitis, eye irritation; thrombophlebitis; dyspnea, epistaxis, cough, rhinorrhea; GI hemorrhage, constipation, upper abdominal pain, dyspepsia, flatulence, dry mouth; hyperbilirubinemia, LFT abnormalities; rash, alopecia, erythema, dry skin, pruritus, skin hyperpigmentation & desquamation, rash macular, dermatitis, pigmentation & nail disorder; pain in extremity, back pain, arthralgia; pyrexia, peripheral edema, malaise, chest pain.
Click to view Bdocin 500 detailed prescribing information
Drug Interactions
Significant interaction w/ brivudine resulting from inhibition of dihydropyrimidine dehydrogenase by brivudine which leads to increased fluoropyrimidine toxicity. Co-administration w/ CYP2C9 substrates. Altered coagulation parameters &/or bleeding w/ coumarin-derivative anticoagulants eg, warfarin & phenprocoumon. Increased phenytoin plasma conc resulting in symptoms of phenytoin intoxication. Pharmacodynamics & toxicity may be enhanced by folinic acid. Increased plasma conc w/ Al & Mg hydroxide-containing antacid. Possible decreased efficacy w/ allopurinol. Decreased absorption rate w/ food.
Click to view Bdocin 500 detailed prescribing information
Storage
View Bdocin 500 storage conditions for details to ensure optimal shelf-life.
Description
View Bdocin 500 description for details of the chemical structure and excipients (inactive components).
Action
View Bdocin 500 mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01BC06 - capecitabine ; Belongs to the class of antimetabolites, pyrimidine analogues. Used in the treatment of cancer.
Regulatory Classification
Rx
Presentation/Packing
Form
Bdocin 500 FC tab 500 mg
Packing/Price
100's;120's